Cargando…

Lymphocyte–C-reactive protein ratio can differentiate disease severity of COVID-19 patients and serve as an assistant screening tool for hospital and ICU admission

In this study, we aimed to explore whether lymphocyte–C-reactive protein ratio (LCR) can differentiate disease severity of coronavirus disease 2019 (COVID-19) patients and its value as an assistant screening tool for admission to hospital and intensive care unit (ICU). A total of 184 adult COVID-19...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jian-Nan, Gao, Yang, Wang, Xin-Tong, Li, Na-Na, Du, Xue, Tang, Yu-Jia, Lai, Qi-Qi, Chen, Peng-Fei, Yue, Chuang-Shi, Wu, Ji-Han, Kang, Kai, Zhao, Ming-Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554799/
https://www.ncbi.nlm.nih.gov/pubmed/36248811
http://dx.doi.org/10.3389/fimmu.2022.957407
_version_ 1784806778657046528
author Zhang, Jian-Nan
Gao, Yang
Wang, Xin-Tong
Li, Na-Na
Du, Xue
Tang, Yu-Jia
Lai, Qi-Qi
Chen, Peng-Fei
Yue, Chuang-Shi
Wu, Ji-Han
Kang, Kai
Zhao, Ming-Yan
author_facet Zhang, Jian-Nan
Gao, Yang
Wang, Xin-Tong
Li, Na-Na
Du, Xue
Tang, Yu-Jia
Lai, Qi-Qi
Chen, Peng-Fei
Yue, Chuang-Shi
Wu, Ji-Han
Kang, Kai
Zhao, Ming-Yan
author_sort Zhang, Jian-Nan
collection PubMed
description In this study, we aimed to explore whether lymphocyte–C-reactive protein ratio (LCR) can differentiate disease severity of coronavirus disease 2019 (COVID-19) patients and its value as an assistant screening tool for admission to hospital and intensive care unit (ICU). A total of 184 adult COVID-19 patients from the COVID-19 Treatment Center in Heilongjiang Province at the First Affiliated Hospital of Harbin Medical University between January 2020 and March 2021 were included in this study. Patients were divided into asymptomatic infection group, mild group, moderate group, severe group, and critical group according to the Diagnosis and Treatment of New Coronavirus Pneumonia (ninth edition). Demographic and clinical data including gender, age, comorbidities, severity of COVID-19, white blood cell count (WBC), neutrophil proportion (NEUT%), lymphocyte count (LYMPH), lymphocyte percentage (LYM%), red blood cell distribution width (RDW), platelet (PLT), C-reactive protein (CRP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine (SCr), albumin (ALB), total bilirubin (TB), direct bilirubin (DBIL), indirect bilirubin (IBIL), and D-dimer were obtained and collated from medical records at admission, from which sequential organ failure assessment (SOFA) score and LCR were calculated, and all the above indicators were compared among the groups. Multiple clinical parameters, including LYMPH, CRP, and LCR, showed significant differences among the groups. The related factors to classify COVID-19 patients into moderate, severe, and critical groups included age, number of comorbidities, WBC, LCR, and AST. Among these factors, the number of comorbidities showed the greatest effect, and only WBC and LCR were protective factors. The area under the receiver operating characteristic (ROC) curve of LCR to classify COVID-19 patients into moderate, severe, and critical groups was 0.176. The cutoff value of LCR and the sensitivity and specificity of the ROC curve were 1,780.7050 and 84.6% and 66.2%, respectively. The related factors to classify COVID-19 patients into severe and critical groups included the number of comorbidities, PLT, LCR, and SOFA score. Among these factors, SOFA score showed the greatest effect, and LCR was the only protective factor. The area under the ROC curve of LCR to classify COVID-19 patients into severe and critical groups was 0.106. The cutoff value of LCR and the sensitivity and specificity of the ROC curve were 571.2200 and 81.3% and 90.0%, respectively. In summary, LCR can differentiate disease severity of COVID-19 patients and serve as a simple and objective assistant screening tool for hospital and ICU admission.
format Online
Article
Text
id pubmed-9554799
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95547992022-10-13 Lymphocyte–C-reactive protein ratio can differentiate disease severity of COVID-19 patients and serve as an assistant screening tool for hospital and ICU admission Zhang, Jian-Nan Gao, Yang Wang, Xin-Tong Li, Na-Na Du, Xue Tang, Yu-Jia Lai, Qi-Qi Chen, Peng-Fei Yue, Chuang-Shi Wu, Ji-Han Kang, Kai Zhao, Ming-Yan Front Immunol Immunology In this study, we aimed to explore whether lymphocyte–C-reactive protein ratio (LCR) can differentiate disease severity of coronavirus disease 2019 (COVID-19) patients and its value as an assistant screening tool for admission to hospital and intensive care unit (ICU). A total of 184 adult COVID-19 patients from the COVID-19 Treatment Center in Heilongjiang Province at the First Affiliated Hospital of Harbin Medical University between January 2020 and March 2021 were included in this study. Patients were divided into asymptomatic infection group, mild group, moderate group, severe group, and critical group according to the Diagnosis and Treatment of New Coronavirus Pneumonia (ninth edition). Demographic and clinical data including gender, age, comorbidities, severity of COVID-19, white blood cell count (WBC), neutrophil proportion (NEUT%), lymphocyte count (LYMPH), lymphocyte percentage (LYM%), red blood cell distribution width (RDW), platelet (PLT), C-reactive protein (CRP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine (SCr), albumin (ALB), total bilirubin (TB), direct bilirubin (DBIL), indirect bilirubin (IBIL), and D-dimer were obtained and collated from medical records at admission, from which sequential organ failure assessment (SOFA) score and LCR were calculated, and all the above indicators were compared among the groups. Multiple clinical parameters, including LYMPH, CRP, and LCR, showed significant differences among the groups. The related factors to classify COVID-19 patients into moderate, severe, and critical groups included age, number of comorbidities, WBC, LCR, and AST. Among these factors, the number of comorbidities showed the greatest effect, and only WBC and LCR were protective factors. The area under the receiver operating characteristic (ROC) curve of LCR to classify COVID-19 patients into moderate, severe, and critical groups was 0.176. The cutoff value of LCR and the sensitivity and specificity of the ROC curve were 1,780.7050 and 84.6% and 66.2%, respectively. The related factors to classify COVID-19 patients into severe and critical groups included the number of comorbidities, PLT, LCR, and SOFA score. Among these factors, SOFA score showed the greatest effect, and LCR was the only protective factor. The area under the ROC curve of LCR to classify COVID-19 patients into severe and critical groups was 0.106. The cutoff value of LCR and the sensitivity and specificity of the ROC curve were 571.2200 and 81.3% and 90.0%, respectively. In summary, LCR can differentiate disease severity of COVID-19 patients and serve as a simple and objective assistant screening tool for hospital and ICU admission. Frontiers Media S.A. 2022-09-23 /pmc/articles/PMC9554799/ /pubmed/36248811 http://dx.doi.org/10.3389/fimmu.2022.957407 Text en Copyright © 2022 Zhang, Gao, Wang, Li, Du, Tang, Lai, Chen, Yue, Wu, Kang and Zhao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zhang, Jian-Nan
Gao, Yang
Wang, Xin-Tong
Li, Na-Na
Du, Xue
Tang, Yu-Jia
Lai, Qi-Qi
Chen, Peng-Fei
Yue, Chuang-Shi
Wu, Ji-Han
Kang, Kai
Zhao, Ming-Yan
Lymphocyte–C-reactive protein ratio can differentiate disease severity of COVID-19 patients and serve as an assistant screening tool for hospital and ICU admission
title Lymphocyte–C-reactive protein ratio can differentiate disease severity of COVID-19 patients and serve as an assistant screening tool for hospital and ICU admission
title_full Lymphocyte–C-reactive protein ratio can differentiate disease severity of COVID-19 patients and serve as an assistant screening tool for hospital and ICU admission
title_fullStr Lymphocyte–C-reactive protein ratio can differentiate disease severity of COVID-19 patients and serve as an assistant screening tool for hospital and ICU admission
title_full_unstemmed Lymphocyte–C-reactive protein ratio can differentiate disease severity of COVID-19 patients and serve as an assistant screening tool for hospital and ICU admission
title_short Lymphocyte–C-reactive protein ratio can differentiate disease severity of COVID-19 patients and serve as an assistant screening tool for hospital and ICU admission
title_sort lymphocyte–c-reactive protein ratio can differentiate disease severity of covid-19 patients and serve as an assistant screening tool for hospital and icu admission
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554799/
https://www.ncbi.nlm.nih.gov/pubmed/36248811
http://dx.doi.org/10.3389/fimmu.2022.957407
work_keys_str_mv AT zhangjiannan lymphocytecreactiveproteinratiocandifferentiatediseaseseverityofcovid19patientsandserveasanassistantscreeningtoolforhospitalandicuadmission
AT gaoyang lymphocytecreactiveproteinratiocandifferentiatediseaseseverityofcovid19patientsandserveasanassistantscreeningtoolforhospitalandicuadmission
AT wangxintong lymphocytecreactiveproteinratiocandifferentiatediseaseseverityofcovid19patientsandserveasanassistantscreeningtoolforhospitalandicuadmission
AT linana lymphocytecreactiveproteinratiocandifferentiatediseaseseverityofcovid19patientsandserveasanassistantscreeningtoolforhospitalandicuadmission
AT duxue lymphocytecreactiveproteinratiocandifferentiatediseaseseverityofcovid19patientsandserveasanassistantscreeningtoolforhospitalandicuadmission
AT tangyujia lymphocytecreactiveproteinratiocandifferentiatediseaseseverityofcovid19patientsandserveasanassistantscreeningtoolforhospitalandicuadmission
AT laiqiqi lymphocytecreactiveproteinratiocandifferentiatediseaseseverityofcovid19patientsandserveasanassistantscreeningtoolforhospitalandicuadmission
AT chenpengfei lymphocytecreactiveproteinratiocandifferentiatediseaseseverityofcovid19patientsandserveasanassistantscreeningtoolforhospitalandicuadmission
AT yuechuangshi lymphocytecreactiveproteinratiocandifferentiatediseaseseverityofcovid19patientsandserveasanassistantscreeningtoolforhospitalandicuadmission
AT wujihan lymphocytecreactiveproteinratiocandifferentiatediseaseseverityofcovid19patientsandserveasanassistantscreeningtoolforhospitalandicuadmission
AT kangkai lymphocytecreactiveproteinratiocandifferentiatediseaseseverityofcovid19patientsandserveasanassistantscreeningtoolforhospitalandicuadmission
AT zhaomingyan lymphocytecreactiveproteinratiocandifferentiatediseaseseverityofcovid19patientsandserveasanassistantscreeningtoolforhospitalandicuadmission